Professor Udai Banerji champions multidisciplinary working at the interface between early phase clinical trials, drug discovery and translational research related to drug resistance.

He is a key member of the Cancer Therapeutics Unit, providing early clinical insights into areas of unmet need and clinical relevance during target prioritisation. He leads the Clinical Pharmacodynamics Biomarker Group, which plays a crucial role in transferring pharmacodynamic biomarkers used in drug discovery on to platforms that can be used in clinical trials.